الرئيسية
استكشاف
nav.journalClub
الرائج
المزيد
Synapse
⌘+K
Synapse
اللغة
العربية
العربية
Table 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit | Synapse
September 16, 2025
Open Access
View Full Paper
Table 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit
CX
Camila Bragança Xavier
The University of Texas MD Anderson Cancer Center
CA
Clark R. Andersen
The University of Texas MD Anderson Cancer Center
JL
JoAnn Lim
The University of Texas MD Anderson Cancer Center
See all
Key Points
The analysis shows how drug interactions affect treatment outcomes in patients with solid tumors, improving patient management.
Patients undergoing immunotherapy for solid tumors had varied responses based on identified drug interactions.
Using a drug interaction framework, the research draws upon data collected in a Phase I unit for improved outcomes in treatment.
The findings may inform future immunotherapy strategies, enabling better tailored treatments for solid tumor patients.
Abstract
Response data according to therapy type.
اسأل الذكاء الاصطناعي
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
اسأل الذكاء الاصطناعي
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Cite This Study
Copy
Xavier et al. (Mon,) studied this question.
synapsesocial.com/papers/68d4508931b076d99fa5873e
https://doi.org/https://doi.org/10.1158/2767-9764.30126780